Loss-of-function mutations in the NF1 tumor suppressor gene underlie the familial cancer syndrome neurofibromatosis type 1. More recently NF1 mutations have been detected in sporadic tumors, suggesting that NF1 plays an even broader role in human cancer. The overall goal of this application is to elucidate the molecular mechanisms by which NF1 inactivation promotes tumorigenesis. The NF1- encoded protein, neurofibromin, functions as a Ras-GTPase activating protein (RasGAP). Accordingly, deregulation of Ras contributes to NF1 development;however, the precise molecular function of neurofibromin remains unclear. Thus the goals of this application are to 1) establish a new function of neurofibromin and define a novel effector pathway involved in tumorigenesis and 2) systematically define the NF1 tumor suppressor network as it relates to the Ras pathway. An additional goal is to elucidate how NF1 mutations participate in a previously unrecognized sporadic tumor-type. To accomplish these aims we will be using cell biological, genetic, biochemical and some mouse modeling approaches. Collectively these studies will not only provide a comprehensive understanding of how neurofibromin regulates the Ras pathway, should identify the most critical therapeutic targets in this pathway, which may ultimately impact therapeutic development and treatments.

Public Health Relevance

The goal of this application is to investigate how mutations in the NF1 tumor suppressor promote cancer. This research will improve our understanding of the familial cancer syndrome NF1 and will also provide insight into other sporadic cancers, such as brain cancer and melanoma. This work is also likely to impact therapeutic development for these diseases.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Molecular Oncogenesis Study Section (MONC)
Program Officer
Yassin, Rihab R,
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Liao, Sida; Maertens, Ophélia; Cichowski, Karen et al. (2018) Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is. Genes Dev 32:1188-1200
Malone, Clare F; Emerson, Chloe; Ingraham, Rachel et al. (2017) mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. Cancer Discov 7:1450-1463
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
Lock, Rebecca; Ingraham, Rachel; Maertens, Ophélia et al. (2016) Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J Clin Invest 126:2181-90
Malone, Clare F; Fromm, Jody A; Maertens, Ophélia et al. (2014) Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov 4:1062-73
Hollstein, Pablo E; Cichowski, Karen (2013) Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. Cancer Discov 3:880-93
McLaughlin, Sara Koenig; Olsen, Sarah Naomi; Dake, Benjamin et al. (2013) The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell 24:365-78
Maertens, Ophélia; Johnson, Bryan; Hollstein, Pablo et al. (2013) Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 3:338-49
McGillicuddy, Lauren T; Fromm, Jody A; Hollstein, Pablo E et al. (2009) Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16:44-54
Johannessen, Cory M; Johnson, Bryan W; Williams, Sybil M Genther et al. (2008) TORC1 is essential for NF1-associated malignancies. Curr Biol 18:56-62

Showing the most recent 10 out of 11 publications